Yüklüyor......
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the...
Kaydedildi:
| Yayımlandı: | Ther Adv Hematol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7874350/ https://ncbi.nlm.nih.gov/pubmed/33613931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989586 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|